NEW YORK (GenomeWeb) – At the annual meeting of the American Association for Cancer Research in Washington D.C. this week, representatives from Foundation Medicine presented new data on the company's adaptation of its comprehensive genomic profiling to predict tumor mutational burden and guide the use of immunotherapies.

The company also presented data offering new insights into specific molecular changes that appear to influence response to these increasingly popular drugs.